What is the 13F Pro Quality Score for NRC?

13F Pro ranks NRC HEALTH (NRC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NRC's current score at https://13fpro.ai/research/NRC (free sign-up required for the full ranking).

Where does 13F Pro source NRC data?

All NRC HEALTH fundamentals and ownership data come directly from SEC EDGAR. NRC HEALTH files with the SEC under CIK 70487. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NRC in?

NRC HEALTH (NRC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NRC research updated on 13F Pro?

NRC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NRC HEALTH(NRC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 70487 NRC stock profile & AI dashboard →

13F Pro Quality Score

46.1/100

Rank #1,680 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

23.1/100

Profitability

52.7/100

Balance Sheet

86.0/100

Earnings Quality

11.7/100

Free Cash Flow

65.6/100

Institutional Flow

53.0/100

Revenue Scale

20.3/100

Dilution Risk

37.9/100

NRC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NRC HEALTH (NRC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NRC at 46.1/100 on a 32-signal composite quality model, placing it at rank #1,680 of 2,879 stocks — the bottom half of the AI-ranked universe. NRC scores in the top quartile across balance sheet strength (86.0). Areas of concern include earnings quality (11.7) and revenue scale (20.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), NRC HEALTH reports quarterly revenue of $34.8M, net income of $3.2M, an operating margin of 16.0%. Top institutional holders of NRC by reported 13-F value include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT, MORGAN STANLEY, BlackRock,, based on the most recent SEC filings. NRC trades on the Nasdaq exchange and files with the SEC under CIK 70487. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NRC HEALTH directly from SEC EDGAR. NRC HEALTH's 13F Pro composite quality score has ranged between 46 and 73 since 2021, currently 46.1 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

Revenue

Q1 2026

$34.8M

Net Income

Q1 2026

$3.2M

Free Cash Flow

Q1 2026

$5.3M

Operating Margin

Q1 2026

16.0%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-3.7% YoY

$143.1MFY 2024

FY21 $148.0MFY22 $151.6MFY23 $148.6MFY24 $143.1M

Net Income

-20.0% YoY

$24.8MFY 2024

FY21 $37.5MFY22 $31.8MFY23 $31.0MFY24 $24.8M

Operating Income

-12.1% YoY

$35.2MFY 2024

FY21 $50.3MFY22 $46.5MFY23 $40.0MFY24 $35.2M

EPS (Diluted)

-16.8% YoY

$1.04FY 2024

FY21 $1.46FY22 $1.27FY23 $1.25FY24 $1.04

Total Assets

+8.3% YoY

$132.5MFY 2024

FY21 $157.5MFY22 $130.5MFY23 $122.4MFY24 $132.5M

Total Debt

+57.4% YoY

$57.9MFY 2024

FY21 $26.6MFY22 $22.3MFY23 $36.8MFY24 $57.9M

Op. Cash Flow

-9.2% YoY

$34.6MFY 2024

FY21 $46.3MFY22 $36.3MFY23 $38.1MFY24 $34.6M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$143.1M -3.7%	$148.6M -2.0%	$151.6M +2.4%	$148.0M +11.0%	$133.3M +4.1%	$128.0M
Net Income	$24.8M -20.0%	$31.0M -2.6%	$31.8M -15.1%	$37.5M	—	—
Operating Income	$35.2M -12.1%	$40.0M -14.0%	$46.5M -7.4%	$50.3M +17.8%	$42.7M -0.8%	$43.0M
EPS (Diluted)	$1.04 -16.8%	$1.25 -1.6%	$1.27 -13.0%	$1.46 +0.7%	$1.45 +15.1%	$1.26
Total Assets	$132.5M +8.3%	$122.4M -6.2%	$130.5M -17.2%	$157.5M +18.1%	$133.4M +20.5%	$110.7M
Total Debt	$57.9M +57.4%	$36.8M +64.9%	$22.3M -16.2%	$26.6M -13.3%	$30.7M -10.4%	$34.3M
Operating Cash Flow	$34.6M -9.2%	$38.1M +5.1%	$36.3M -21.7%	$46.3M +14.0%	$40.6M -0.7%	$40.9M

AI Insight: NRC Financial Trends

NRC Health's debt burden surged 124% from Q2 2024 to Q1 2026 while equity collapsed 68%, creating severe balance sheet deterioration despite stable revenue.

• Total debt exploded from $33M in Q2 2024 to $74M in Q1 2026, a 124% increase.

• Shareholder equity plummeted 68% from $40M in Q2 2024 to $13M in Q1 2026.

• Revenue remained relatively stable, fluctuating between $34M-$37M across the eight quarters.

• Operating income deteriorated from $9M in Q2 2024 to $2M in Q2 2025 before recovering to $6M in Q1 2026.

⚠ Operating cash flow turned negative in Q2 2025 at -$1M, first negative reading in the period.

⚠ Debt-to-equity ratio deteriorated dramatically as leverage increased while equity base eroded.

AI Insight: NRC Ratio Trends

Operating margin collapsed from 25.6% in Q1 2025 to 4.7% in Q2 2025, while debt-to-equity ratio surged from 0.83 to 5.48 over the period.

• Operating margin plummeted from 25.6% in Q1 2025 to 4.7% in Q2 2025 before partially recovering to 16.0% in Q1 2026.

• ROIC declined from 48.2% in Q2 2024 to 25.4% in Q1 2026, with a severe drop to 6.5% in Q2 2025.

• Debt-to-equity ratio increased dramatically from 0.83 in Q2 2024 to 5.48 in Q1 2026, indicating rising leverage.

⚠ Q2 2025 appears to contain significant one-off impacts given the severe margin and ROIC deterioration that quarter.

⚠ Leverage has quintupled since Q2 2024, reaching concerning levels above 5x debt-to-equity by Q1 2026.

Get alerted when NRC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NRC HEALTH including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NRC

KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
$44.8M2,636,355 sh
MORGAN STANLEY
$17.0M1,001,880 sh
BlackRock, Inc.
$16.6M975,855 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.3M662,837 sh
DIMENSIONAL FUND ADVISORS LP
$8.3M489,740 sh
GEODE CAPITAL MANAGEMENT, LLC
$6.7M393,847 sh
RENAISSANCE TECHNOLOGIES LLC
$5.8M340,784 sh
STATE STREET CORP
$5.2M300,748 sh
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC
$4.9M286,840 sh
NORTHERN TRUST CORP
$4.3M255,601 sh

Fund	Value	Shares
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC	$44.8M	2,636,355
MORGAN STANLEY	$17.0M	1,001,880
BlackRock, Inc.	$16.6M	975,855
VANGUARD CAPITAL MANAGEMENT LLC	$11.3M	662,837
DIMENSIONAL FUND ADVISORS LP	$8.3M	489,740
GEODE CAPITAL MANAGEMENT, LLC	$6.7M	393,847
RENAISSANCE TECHNOLOGIES LLC	$5.8M	340,784
STATE STREET CORP	$5.2M	300,748
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC	$4.9M	286,840
NORTHERN TRUST CORP	$4.3M	255,601

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NRC on your watchlist

Track score changes the day NRC HEALTH files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NRC a good stock to buy?

13F Pro's AI-powered analysis of NRC HEALTH (NRC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NRC are available on the NRC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NRC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NRC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NRC HEALTH's investment landscape.